Halpern et al. (2009HALPERN, R.; BARGHOUT, V.; ZAROTSKY, V.; WILLIAMS, D.E. Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. JCOM, v.16, n.5, p.215-23, 2009.), USA |
374 (CML) 465 (in total) |
Mean 50.8 + 14,1 years |
CP |
Minimum of 12 months |
Retrospective Cohort |
MPR |
A: 70.1% |
------- |
Noens et al. (2009NOENS, L.; VAN LIERDE, M.A.; DE BOCK, R.; VERHOEF, G.; ZACHÉE, P.; BERNEMAN, Z.; MARTIAT, P.; MINEUR, P.;, VAN EYGEN, K.; MACDONALD, K.; DE GEEST, S.; ALBRECHT, T.; ABRAHAM, I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood , v.113, n.22, p.5401-11, 2009.), Spain |
169 |
17-86 years |
AP / CP |
90 days |
Prospective Observational |
Structured questionnaire/ Manual tablet count |
A: 67.3% D: 1.8% |
Higher age, male sex, longer time since CML diagnosis, living alone, imatinib dose > 600 mg/day |
Marin et al. (2010MARIN, D.; BAZEOS, A.; MAHON, F.X.; ELIASSON, L.; MILOJKOVIC, D.; BUA, M.; APPERLEY, J.F.; SZYDLO, R.; DESAI, R.; KOZLOWSKI, K.; PALIOMPEIS, C.; LATHAM, V.; FORONI, L.; MOLIMARD, M.; REID, A.; REZVANI, K.; DE LAVALLADE, H.; GUALLAR, C.; GOLDMAN, J.; KHORASHAD, J.S. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol., v.28, n.14, p.2381-8, 2010.), UK |
87 |
25.5-89 years |
CP |
91 days |
Clinical study |
MEMS/Imatinib plasma levels |
A: 74% |
Younger patients, ADR, Imatinib Dose > 400 mg/day |
Eliasson et al. (2011ELIASSON, L.; CLIFFORD, S.; BARBER, N.; MARIN, D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk. Res. , v.35, n.5, p.626-30, 2011.), UK |
21 |
26-70 years |
CP |
------ |
Cross-sectional |
MEMS/Questionnaire |
A: 19% |
Forgetting, no imatinib available at pharmacy, ADR, travelling, socialising/drinking alcohol |
Efficaceet al. (2012), USA |
413 |
20-87 years |
CP |
------ |
Cross-sectional |
Structured questionnaire |
A: 53% |
Mental health dysfunction, lower level of social support |
Jönsson et al. (2012JÖNSSON, S.; OLSSON, B.; SÖDERBERG, J.; WADENVIK, H. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study. Ann. Hematol., v.91, n.5, p.679-85, 2012.), Sweden |
38 |
26-88 years |
CP |
12 months |
Prospective Cohort |
Structured Questionnaire |
A: 97% |
Lower level of information, difficult access to the treating clinic |
Cid et al. (2013CID, D.M; MAGALHÃES, S.M.; QUIXADÁ, A.T.; HONÓRIO, R.P.; COSTA, P.F.; REIS, S.R.; CARVALHO, S.M.; CID, D.A.; SUCUPIRA, R.M.; DE OLIVEIRA, M.F. Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital. Rev.Bras. Hematol. Hemoter. v.35, n.6, p.389-94, 2013.), Brazil |
100 |
21-40 years |
AP/ BP/ CP |
------- |
Retrospective Descriptive |
MPR |
A: 53% D: 17% |
ADR/ Intolerance |
Hirji et al. (2013HIRJI, I.; GUPTA, S.; GOREN, A.; CHIROVSKY, D.R.; MOADEL, A.B.; OLAVARRIA, E.; VICTOR, T.W.; DAVIS, C.C. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Health Qual. Life Outcomes, v.11, p.167, 2013. DOI: 10.1186/1477-7525-11-167.), USA |
303 |
Mean 51.5 + 13.6 years |
CP |
------- |
Cross-sectional |
Online Questionnaire |
A: 66% |
CML treatment restrictions or requirements |
Reis et al. (2013REIS, S.R.; QUIXADÁ, A.T.; NUNES, S.T.; CID, D.M.; DE SOUZA, J.H.; DA COSTA, C.M.; SILVEIRA, C.B.; CID, D.A.; DE OLIVEIRA, M.F. Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital. Rev. Bras. Hematol. Hemoter., v.35, n.3, p.174-9, 2013.), Brazil |
100 |
13-77 years |
AP/ BP/ CP |
------- |
Retrospective Descriptive |
MPR |
A: 53% D: 41% |
Unavailability of the drug, ADR |
Rosa et al. (2013ROSA, V.G.; NICOLAS, F.G.; MORENO RG, ROMERO MV, CARVAJAL TM, PÉREZ RG. Adherencia y toxicidad de los inhibidores de la tirosinquinasa en leucemia mieloide crônica. Farm. Hosp., v.37, n.6, p.434-40, 2013.), Brazil |
25 |
25-88 years |
CP |
18 months |
Retrospective Observational |
Structured Questionnaire |
A: 62.5% |
Higher age, longer treatment, female sex, ADR |
Santoleri et al. (2013SANTOLERI, F.; SORICE, P.; LASALA, R.; RIZZO, R.C.; COSTANTINI, A. Patient adherence and persistence with imatinib, nilotinib, dasatinib in clinical practice. PLoS One.822013 10.1371/journal.pone.0056813.), Italy |
63 |
14-88 years |
CP |
39 months |
Retrospective Observational |
Hospital pharmacy database |
A: 83% D: 10% |
Significant ADR, poor patient involvement in treatment |
Chen et al. (2014CHEN, T.C.; CHEN, L.C.; HUANG, Y.B.; CHANG, C.S. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int. J. Clin. Pharm., v.36, n.1, p.172-81, 2014.), Taiwan |
119 |
Mean 45.7 ± 16.9 years |
CP |
Mean 3.9 ± 2.9 years |
Retrospective Cohort |
MPR/Biological marker |
A: 73.1% D: 38.6% |
ADR, lower level of social and medical support, accessibility problems, ineffectiveness |
Efficaceet al. (2014), Italy |
175 |
20-87 years |
CP |
------- |
Cross-sectional |
Structured Questionnaire |
A: Not assessed* |
ADR, older age, male sex |
Gotta et al. (2014GOTTA, V. ; WIDMER, N. ; DECOSTERD, L.A. ; CHALANDON, Y.; HEIM, D.; GREGOR, M.; BENZ, R. ; LEONCINI-FRANSCINI, L.; BAERLOCHER, G.M.; DUCHOSAL, M.A. ; CSAJKA, C. ; BUCLIN, T. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemother. Pharmacol., v.74, n.6, p.1307-19, 2014. ), Italy |
56 |
44-73 years |
AP / CP |
13 months |
Clinical study |
Drug detection in biological fluids |
D: 23% |
ADR/Intolerance, failure* |